Company news
Theravance Biopharma, Inc. (NASDAQ:TBPH) news
Every Theravance Biopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
June 29, 2026
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 19, 2026
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost R...
March 3, 2026
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Da...
November 20, 2025
Theravance Biopharma to Participate in Upcoming Investor Conferences
November 19, 2025
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
October 29, 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
October 27, 2025
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to...
October 16, 2025
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
October 14, 2025
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Ortho...
August 25, 2025
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
July 28, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
July 23, 2025
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
June 26, 2025
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
June 2, 2025
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
May 9, 2025
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
April 28, 2025
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
April 24, 2025
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
April 7, 2025
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the ...
March 27, 2025
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
December 17, 2024
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
November 12, 2024
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
October 24, 2024
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chron...
October 18, 2024
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
July 22, 2024
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
April 29, 2024
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Sympt...
April 10, 2024
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 26, 2024
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
February 14, 2024
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive ...
January 5, 2024
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
December 21, 2023
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
December 18, 2023
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
November 16, 2023
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 15, 2023
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatmen...
November 13, 2023
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
November 7, 2023
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
October 19, 2023
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
August 28, 2023
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
August 7, 2023
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthost...
May 9, 2023